Verona Pharma (VRP)

 

VRP Share PerformanceMore

52 week high262.25 15/03/16
52 week low120.75 17/02/17
52 week change -39.80 (-24.14%)
4 week volume344,898 27/01/17

Media for (VRP)

Presenter: Jan-Anders Karlsson
27/07/2014

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

First COPD patient dosed with RPL554

RNS Number: 4893X Verona Pharma PLC 22 February 2017 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014. Verona Pharma Commences further RPL554 Phase 2a Clinical Trial First COPD patient dosed with RPL554 as an add-on therapy to tiotropium (Spiriva) Top-lin...

Verona share consolidation approved by shareholders

Verona Pharma has announced that all resolutions proposed at the General Meeting held earlier today were duly passed. A...

Result of General Meeting and Share Consolidation

RNS Number: 3641W Verona Pharma PLC 08 February 2017 Verona Pharma plc ("Verona Pharma" or the "Company") Result of General Meeting Consolidation of Share Capital 8 February 2017, London - Verona Pharma plc (AIM: VRP), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatm...

Publication of Circular

RNS Number: 4091U Verona Pharma PLC 18 January 2017 18 January 2017 FOR RNS RELEASE: THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014. THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN O...

Holding(s) in Company

RNS Number: 8462T Verona Pharma PLC 11 January 2017 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Verona Pharma Plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights X An acq...

Holding(s) in Company

RNS Number: 3219T Verona Pharma PLC 04 January 2017 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Verona Pharma plc 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights An acqu...

Issue of Equity

Verona Pharma plc (?Verona Pharma? or the ?Company?) Exercise of Options Verona Pharma plc (AIM: VRP), the drug development company focused on first-in-class medicines to treat respiratory diseases, announces that it has issued 2,000,000 new ordinary shares in the capital of the Company (the ?New Shares?) following an exercise of share options by a forme...

Verona Pharma plans US public offering

Verona Pharma announces that it plans to conduct a registered initial public offering in the US. The number of shares an...

Fundamental DataMore

EPS-0.73
Dividend yield0 %

Equity Research (VRP)

edison investment research
Verona Pharma plc
26/07/2016
Verona’s £44.7m gross raise removes funding uncertainty, allowing the company to focus on the clinical progress of its respiratory asset RPL554, a dual PDE3/PDE4 inhibitor. RPL554 is in development...
hardman & co
Verona Pharma plc
20/06/2016
VRP is developing first-in-class drugs to treat unmet medical needs in respiratory disease. Over the last two years’ VRP has reported positive outcomes from a five stage Phase I/IIa programme which...
hardman & co
Verona Pharma plc
16/03/2016
VRP is developing first-in-class drugs that treat unmet medical needs in respiratory disease. RPL554 is being fast-tracked to commercialisation by focusing on a $3.2bn market segment poorly serviced...

Latest discussion posts More

  • First Patient Dosed

    Extract: "22 February 2017, London - Verona Pharma plc (AIM: VRP.L) (Verona Pharma), a clinical-stage biopharmaceutical company focused on developing and commercialising ...
    22-Feb-2017
    paulmc1
  • US Listing will be key

    It sort of goes without saying that the price we'll drop to will be linked to the offer price of shares in the US if the offer gets away. That is the the unknown RNS last ...
    17-Feb-2017
    Tired and Confused
  • Re: RNS 13/02/17

    Where do you think that the drop will end? I'm thinking around 115. ---------------------------------------------------------------------------------------- It's pretty ...
    17-Feb-2017
    Balone

Users' HoldingsMore

Users who hold Verona Pharma also hold..
LLOYDS GRP.20%
GULF KEYSTONE11%
RANGE RES.11%
RENEURON10%
BP10%

Codes & Symbols

ISINGB00BYW2KH80
SymbolsVRP, LSE:VRP, VRP.L, VRP:LN, LON:VRP, XLON:VRP